What is Immunotech Laboratories, Inc. (IMMB) stock price today?

Immunotech Laboratories, Inc. (IMMB) is currently trading at $0.00.

What is IMMB P/E ratio?

Immunotech Laboratories, Inc.'s P/E ratio is -0.22. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is IMMB return on equity (ROE)?

Immunotech Laboratories, Inc.'s return on equity (ROE) is 0.00%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Immunotech Laboratories, Inc.'s market cap?

Immunotech Laboratories, Inc. has a market capitalization of $114993.

OTC · Biotechnology

Immunotech Laboratories, Inc. (IMMB) Stock

$0.00 OTC: IMMB Healthcare

Valuation

Metric	Value
Price	$0.00
Market Cap	$114993
P/E Ratio	-0.22
P/B Ratio	0.02
P/S Ratio	0.00
EPS (TTM)	$-0.59
52-Week High	$0.00
52-Week Low	$0.00
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	0.00%
ROA	-4.68%
ROCE	-7.30%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.40
Current Ratio	0.01

Annual Financials (USD)

Metric	2004	2005	2009	2013	2016
Revenue	$0	$0	$0	$0	$0
Operating Profit	$0	$-2.0M	$-1.0M	$-1.0M	$0
Net Profit	$0	$-34.0M	$-1.0M	$-1.0M	$0
EPS	$-43.00	$-802.00	$0.00	$0.00	$0.00
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2004	2005	2009	2013	2016
Total Assets	$0	$0	$10.0M	$11.0M	$11.0M
Total Liabilities	$1.0M	$1.0M	$4.0M	$5.0M	$6.0M
Cash	$0	$0	$0	$0	$0
Borrowings	$0	$0	$1.0M	$2.0M	$2.0M

Cash Flow (USD)

Metric	2004	2005	2009	2013	2016
Operating Cash Flow	$0	$0	—	$0	$0
Investing Cash Flow	$0	$0	—	$0	$0
Financing Cash Flow	$0	$0	—	$0	$0
Net Cash Flow	$0	$0	—	$0	$0
Free Cash Flow	$0	$0	$0	$0	$0

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-5.55
FCF Yield	-27.10%
Quick Ratio	0.00
Interest Coverage	-20.75
Return 1Y	100.00%
Return 3Y	-66.67%
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
BIOIFBiome Grow Inc.	$0.00	—	-0.01	$56208	0.00%
CBGLCannabis Global Inc.	$0.00	—	-3.40	$56821	0.00%
HADVHealth Advance Inc.	$0.00	—	—	$32189	0.00%
IPAHInterpharm Holdings, Inc.	$0.00	—	—	$660	0.00%
MHTXManhattan Scientifics, Inc.	$0.00	—	—	$55928	0.00%

About Immunotech Laboratories, Inc.

Immunotech Laboratories, Inc. develops and commercializes proprietary proteins for use in treating human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), hepatitis, and other immuno-related disorders. Its flagship compound is ITV-1 (immune therapeutic vaccine), a suspension of irreversible pepsin fraction that is used in the treatment of HIV/AIDS and Hepatitis C, as well as to modulate the immune system. The company is headquartered in Monrovia, California. As of June 14, 2017, Immunotech Laboratories, Inc. operates as a subsidiary of Enzolytics, Inc.

Immunotech Laboratories, Inc. (IMMB) stock trades at $0.00 with a market capitalization of $114993. The stock is valued at a price-to-earnings (P/E) ratio of -0.22, price-to-book of 0.02, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.

On profitability, Immunotech Laboratories, Inc. generates a return on equity (ROE) of 0.00%, return on capital employed of -7.30%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.immunotechlab.com